CoChat
Sign Up
Cited by 115

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Back to the future: oral targeted therapy for RA and other autoimmune diseases

O'Shea, John J., Laurence, Arian, McInnes, Iain B.·2013·Nature Reviews Rheumatology
DOI 10.1038/nrrheum.2013.7
Open this paper in CoChat — free account

Abstract

The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents. With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors. These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium. In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments. We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application. We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrrheum.2013.7

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 97

  1. Leonard, W. J. & O'Shea, J. J. JAKs and STATs: biological implications. Ann. Rev. Immunol. 16, 293–322 (1998). · DOI
  2. Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234–4243 (2011). · DOI
  3. Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–878 (2003). · DOI · Paper page
  4. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495–507 (2012). · DOI
  5. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012). · DOI
  6. Kremer, J. M. et al. A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 64, 970–981 (2012). · DOI
  7. Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009). · DOI
  8. Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S. & Zwillich, S. H. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63, 1150–1158 (2011). · DOI
  9. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140–6736(12)61424-X . · DOI
  10. Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012). · DOI
  11. Papp, K. A. et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167, 668–677 (2012). · DOI
  12. Vincenti, F. et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am. J. Transplant. 12, 2446–2456 (2012). · DOI
  13. Fleischmann, R. et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64, 617–629 (2012). · DOI
  14. van der Heijde, D. et al. Tofacitinib, an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month phase 3 study [abstract 1277]. Arthritis Rheum. 64 (Suppl.), S546 (2012).
  15. Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721–2730 (2012). · DOI
  16. Verstovsek, S. Ruxolitinib: the first agent approved for myelofibrosis. Clin. Adv. Hematol. Oncol. 10, 111–113 (2012).
  17. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787–798 (2012). · DOI · Paper page
  18. Greenwald, M. W. et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract 2172]. Arthritis Rheum. 62 (Suppl.), S911 (2010).
  19. Smolen, J. S. et al. 12- and 24-week patient-reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 490]. Arthritis Rheum. 64 (Suppl.), S214 (2012).
  20. Genovese, M. C. et al. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 2487]. Arthritis Rheum. 64 (Suppl.), S1049–S1050 (2012).
  21. Peterfy, C. G. et al. Magnetic resonance imaging substudy in a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 2488]. Arthritis Rheum. 64 (Suppl.), S1050–S1051 (2012).
  22. O'Shea, J. J. & Plenge, R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36, 542–550 (2012). · DOI
  23. Conklyn, M., Andresen, C., Changelian, P. & Kudlacz, E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J. Leukoc. Biol. 76, 1248–1255 (2004). · DOI
  24. Paniagua, R. et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80, 1283–1292 (2005). · DOI
  25. Maeshima, K. et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-γ and IL-17 production by human CD4+ T cells. Arthritis Rheum. 64, 1790–1798 (2012). · DOI
  26. Labranche, T. P. et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 64, 3531–3542 (2012). · DOI
  27. Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H. & Berg, L. J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking JAK3. Science 270, 794–797 (1995). · DOI
  28. Macchi, P. et al. Mutations of JAK-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995). · DOI
  29. Russell, S. M. et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 270, 797–800 (1995). · DOI
  30. Nosaka, T. et al. Defective lymphoid development in mice lacking Jak3. Science 270, 800–802 (1995). · DOI
  31. Rodig, S. J. et al. Disruption of the JAK1 gene demonstrates obligatory and nonredundant roles of the JAKs in cytokine-induced biologic responses. Cell 93, 373–383 (1998). · DOI
  32. Stump, K. L. et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res. Ther. 13, R68 (2011). · DOI
  33. Kawasaki, M. et al. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 20, 1231–1239 (2011). · DOI
  34. Wang, S. et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 19, 1171–1180 (2010). · DOI
  35. Kudlacz, E., Conklyn, M., Andresen, C., Whitney-Pickett, C. & Changelian, P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol. 582, 154–161 (2008). · DOI
  36. Fleischmann, R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr. Opin. Rheumatol. 24, 335–341 (2012). · DOI
  37. Vanhoutte, F., Mazur, M., Van der Aa, A., Wigerinck, P. & van 't Klooster, G. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634 [abstract 2489]. Arthritis Rheum. 64 (Suppl.), S1051 (2012).
  38. Namour, F. et al. Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2 [abstract 1331]. Arthritis Rheum. 64 (Suppl.), S573 (2012).
  39. Samelson, L. E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20, 371–394 (2002). · DOI
  40. Chu, D. H., Morita, C. T. & Weiss, A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol. Rev. 165, 167–180 (1998). · DOI
  41. Kurosaki, T. Genetic analysis of B cell antigen receptor signaling. Annu. Rev. Immunol. 17, 555–592 (1999). · DOI
  42. Gilfillan, A. M. & Rivera, J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 228, 149–169 (2009). · DOI
  43. Chan, A. C., Irving, B. A. & Weiss, A. New insights into T-cell antigen receptor structure and signal transduction. Curr. Opin. Immunol. 4, 246–251 (1992). · DOI
  44. Chan, A. C. et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264, 1599–1601 (1994). · DOI
  45. Cambier, J. C., Pleiman, C. M. & Clark, M. R. Signal transduction by the B cell antigen receptor and its coreceptors. Annu. Rev. Immunol. 12, 457–486, (1994). · DOI
  46. Turner, M. et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378, 298–302 (1995). · DOI · Paper page
  47. Abtahian, F. et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 299, 247–251 (2003). · DOI
  48. Pine, P. R. et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244–257 (2007). · DOI
  49. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a SYK kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008). · DOI
  50. Genovese, M. C. et al. An oral SYK kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63, 337–345 (2011). · DOI
  51. Barr, P. M. et al. Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin. Immunol. 142, 237–242 (2012). · DOI
  52. Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433–1444 (2008). · DOI
  53. Deng, G. M., Liu, L., Bahjat, F. R., Pine, P. R. & Tsokos, G. C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 62, 2086–2092 (2010). · DOI
  54. Friedberg, J. W. et al. Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010). · DOI
  55. Gomez-Rodriguez, J., Kraus, Z. J. & Schwartzberg, P. L. Tec family kinases Itk and Rlk/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 278, 1980–1989 (2011). · DOI
  56. Rawlings, D. J. & Witte, O. N. Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol. Rev. 138, 105–119 (1994). · DOI
  57. Thomas, J. D. et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355–358 (1993). · DOI
  58. Horwood, N. J., Urbaniak, A. M. & Danks, L. Tec family kinases in inflammation and disease. Int. Rev. Immunol. 31, 87–103 (2012). · DOI
  59. Ellmeier, W., Abramova, A. & Schebesta, A. Tec family kinases: regulation of FcεRI-mediated mast-cell activation. FEBS J. 278, 1990–2000 (2011). · DOI
  60. Chang, B. Y. et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13, R115 (2011). · DOI
  61. Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010). · DOI · Paper page
  62. Weiss, A., Irving, B. A., Tan, L. K. & Koretzky, G. A. Signal transduction by the T cell antigen receptor. Semin. Immunol. 3, 313–324 (1991).
  63. Yablonski, D. & Weiss, A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv. Immunol. 79, 93–128 (2001). · DOI
  64. Lewis, R. S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19, 497–521 (2001). · DOI · Paper page
  65. Altman, A. & Villalba, M. Protein kinase C-θ (PKCθ): it's all about location, location, location. Immunol. Rev. 192, 53–63 (2003). · DOI
  66. Altman, A. & Kong, K. F. PKCθ: a new target for selective immunosuppression. Expert Rev. Clin. Immunol. 8, 205–208 (2012). · DOI
  67. Fuller, T. F. et al. Protein kinase C inhibition ameliorates posttransplantation preservation injury in rat renal transplants. Transplantation 94, 679–686 (2012). · DOI
  68. Wu, X., Li, J., Zhu, M., Fletcher, J. A. & Hodi, F. S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol. Cancer Ther. 11, 1905–1914 (2012). · DOI
  69. Pagès, F. et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369, 327–329 (1994). · DOI
  70. Jones, R. G. et al. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J. Exp. Med. 196, 335–348 (2002). · DOI
  71. Leslie, N. R., Biondi, R. M. & Alessi, D. R. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. 101, 2365–2380 (2001). · DOI
  72. Edinger, A. L. & Thompson, C. B. Antigen-presenting cells control T cell proliferation by regulating amino acid availability. Proc. Natl Acad. Sci. USA 99, 1107–1109 (2002). · DOI
  73. Rathmell, J. C., Farkash, E. A., Gao, W. & Thompson, C. B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869–6876 (2001). · DOI · Paper page
  74. Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240–4245 (1999). · DOI
  75. Beitz, L. O., Fruman, D. A., Kurosaki, T., Cantley, L. C. & Scharenberg, A. M. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. 274, 32662–32666 (1999). · DOI
  76. Edinger, A. L. & Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276–2288 (2002). · DOI
  77. Murgia, M. G., Jordan, S. & Kahan, B. D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine–prednisone-treated renal transplant patients. Kidney Int. 49, 209–216 (1996). · DOI
  78. Kappos, L. et al. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial [abstract]. J. Neurol. 252 (Suppl. 2), S46 (2005).
  79. Dong, C., Davis, R. J. & Flavell, R. A. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55–72 (2002). · DOI
  80. Rincon, M. MAP-kinase signaling pathways in T cells. Curr. Opin. Immunol. 13, 339–345 (2001). · DOI
  81. Josephs, D. H. & Ross, P. J. Sorafenib in hepatocellular carcinoma. Br. J. Hosp. Med. (Lond.) 71, 451–456 (2010). · DOI
  82. Govindarajan, R., Adusumilli, J., Baxter, D. L., El-Khoueiry, A. & Harik, S. I. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J. Clin. Oncol. 24, e48 (2006). · DOI
  83. Gijtenbeek, J. M., van den Bent, M. J. & Vecht, C. J. Cyclosporine neurotoxicity: a review. J. Neurol. 246, 339–346 (1999). · DOI
  84. Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. & Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch. Pharmacol. 374, 311–316 (2007). · DOI
  85. Su, B. et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77, 727–736 (1994). · DOI
  86. Dong, C. et al. Defective T cell differentiation in the absence of Jnk1. Science 282, 2092–2095 (1998). · DOI
  87. Yang, D. D. et al. Differentiation of CD4+ T cells to TH1 cells requires MAP kinase JNK2. Immunity 9, 575–585 (1998). · DOI
  88. Arbour, N. et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8+ T cell-mediated antiviral immunity. J. Exp. Med. 195, 801–810 (2002). · DOI
  89. Conze, D. et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8+ T cell activation. J. Exp. Med. 195, 811–823 (2002). · DOI
  90. Ip, Y. T. & Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)—from inflammation to development. Curr. Opin. Cell Biol. 10, 205–219 (1998). · DOI
  91. Swantek, J. L., Cobb, M. H. & Geppert, T. D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell. Biol. 17, 6274–6282 (1997). · DOI
  92. Ishizuka, T. et al. Mast cell tumor necrosis factor α production is regulated by MEK kinases. Proc. Natl Acad. Sci. USA 94, 6358–6363 (1997). · DOI
  93. Manning, A. M. & Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2, 554–565 (2003). · DOI · Paper page
  94. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994). · DOI
  95. Dominguez, C., Powers, D. A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. 8, 421–430 (2005).
  96. Dyckman, A. J. et al. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 21, 4633–4637 (2011). · DOI
  97. Cohen, S. & Fleischmann, R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr. Opin. Rheumatol. 22, 330–335 (2010). · DOI

Cited by

Sorted by citations

Metadata

Authors
O'Shea, J. J., Laurence, A., & McInnes, I. B.
Venue
Nature Reviews Rheumatology
Publisher
Springer Science and Business Media LLC
Published
2013-02-19
Volume
9
Issue
3
Pages
173-182
ISSN
  • 1759-4790
  • 1759-4804
DOI
10.1038/nrrheum.2013.7
Cited by
115
References
5
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review